OBI-833 completes its Phase 1 cohort expansion study, proceeding to Phase 2 as planned

1. Date of occurrence of the event: May 5, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office 4. Reciprocal shareholding ratios: Not applicable 5. Cause of occurrence: Assessment of the primary endpoint of safety and secondary endpoints of immune response and tumor response […]

This article is password protected.

To view the content, please enter your password in the field below